In case you missed it, a new report from the Association for Accessible
Medicines (AAM) and Biosimilars Council found generic and biosimilar
medications saved American patients and the U.S. health care system $467
billion in 2024 by reducing reliance on higher priced brand name drugs. Savings
over the last decade amounted to a staggering $3.4 trillion.





 

September 12, 2025



TOPLINE



In case you missed it, a new report
<[link removed]> from the
Association for Accessible Medicines (AAM) and Biosimilars Council found
generic and biosimilar medications saved American patients and the U.S. health
care system $467 billion in 2024 by reducing reliance on higher priced brand
name drugs. Savings over the last decade amounted to a staggering $3.4 trillion.



Although brand name drugs make up just one in ten U.S. prescriptions filled,
they represent a staggering 88 percent of prescription drug expenditures. In
contrast, generic medicines account for nine in ten of all prescriptions filled
in the U.S. yet comprise only 12 percent of total prescription drug spending.
This stark imbalance underscores how pharmaceutical companies engage in
anticompetitive tactics to keep brand name drug prices high and maintain market
dominance.



A recent study
<[link removed]>
published in JAMA Health Forum recently found lost competition due to Big
Pharma’s patent thickets on just four widely prescribed brand name drugs cost
patients, taxpayers and the U.S. health care system more than $3.5 billion over
two years due to lost competition. Read more onHERE
<[link removed]>
.



QUOTES OF THE WEEK



“By a very large margin, Granite State voters view pharmaceutical companies to
be most responsible for increases in the costs of prescription drugs.”



Jonathan Klinger, Head of Polling, Praecones Analytica
<[link removed]>



DATA POINTS YOU SHOULD KNOW



$142 Billion



Last year, competition from generic medications produced $142 billion in
savings for Medicare, according to thereport
<[link removed]> from AAM
and the IQVIA Institute.



TWEETS OF THE WEEK



@realtahiramin <[link removed]>: “A
new study in @JAMA_current by Dongzhe Hong, @SeanTu2, and Reed F. Beall looks
at the cost of extended market exclusivities due to patent term extensions and
patent gaming.
[link removed]
<[link removed]>”



@AccessibleMeds <[link removed]>:
“Last year, generic medicines comprised 90 percent of all prescriptions filled,
but only 12 percent of prescription spending. In sharp contrast, brand drugs
supported patients less often— making up only 10 percent of prescriptions
filled but adding up to 88 percent of the total drug spend. This means that in
just one year, Americans spent $98 billion on prescription generic medicines
and a whopping $700 billion on brand drugs. Learn more about how generic
medicines drive healthcare savings and help patients thrive. Visit:
[link removed]
<[link removed]>”



ROAD TO RECOVERY



Forbes: How Can Biosimilars Capture Market Share From Biologic Drugs?
<[link removed]>



Biologic drugs, made from living organisms and usually taken by injection or
infusion, are expensive treatments for complex chronic conditions such as
cancer and autoimmune diseases. Biosimilars, clinically comparable to biologics
and priced lower, create cost-saving opportunities for patients and plan
sponsors. Many hoped that biosimilars would quickly gain ground once they
entered the market. However, the reality has been disappointing.



PHARMA’S POOR PROGNOSIS



NH Journal: Poll Shows Granite Staters Blame Big Pharma For High Drug Costs
<[link removed]>



In the debate over how to address high drug costs for U.S. consumers,
President Donald Trump pointed the finger at Big Pharma, blaming it for the
price Americans pay for medications. In a letter to drug manufacturers earlier
this summer, Trump demanded that they take a series of steps to lower the cost
of drugs. “If you refuse to step up, we will deploy every tool in our arsenal
to protect American families from continued abusive drug pricing practices,” he
wrote. “Americans are demanding lower drug prices, and they need them today.”
And an NHJournal/Praecones Analytica poll of Granite State voters shows they
agree.



Reuters: Eli Lilly Loses Appeal Of $183.7 Million Medicaid Fraud Award
<[link removed]>



A federal appeals court on Thursday rejected Eli Lilly's (LLY.N), opens new
tab appeal of an $183.7 million judgment won by a whistleblowing lawyer and
pharmacist who accused the drugmaker of defrauding Medicaid. The 7th U.S.
Circuit Court of Appeals in Chicago said a federal jury reasonably found that
Lilly knowingly concealed having retroactively increased prices on some drugs,
and then failing to rebate Medicaid on the higher prices.



Alabama Political Reporter: Americans Pay Triple For Prescriptions While Big
Pharma Reaps Profits
<[link removed]>



As Congress reconvenes, the fight over prescription drug costs is once again
front and center. The Pharmaceutical Reform Alliance, a consumer advocacy group
dedicated to lowering medication costs, is sounding the alarm that Americans
are consistently paying the highest prices in the world for the same treatments
available elsewhere at a fraction of the cost. The group argues that without
serious reforms, families will continue to bear impossible financial burdens
just to access lifesaving care. The disparities are staggering.



###



























Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>